{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:47:51Z","timestamp":1792097271400,"version":"4.4.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2634-F-039-001 -"],"award-info":[{"award-number":["114-2634-F-039-001 -"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2639-B-039-001 -ASP"],"award-info":[{"award-number":["NSTC 114-2639-B-039-001 -ASP"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW114-TDU-B-222-144016"],"award-info":[{"award-number":["MOHW114-TDU-B-222-144016"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW114-TDU-B-222-000020"],"award-info":[{"award-number":["MOHW114-TDU-B-222-000020"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2025.218225","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:07:17Z","timestamp":1766164037000},"page":"218225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer"],"prefix":"10.1016","volume":"639","author":[{"given":"Mahdieh","family":"Safaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1725-0079","authenticated-orcid":false,"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Hua","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srimathi","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-5939","authenticated-orcid":false,"given":"Yu-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Soon","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1669-0037","authenticated-orcid":false,"given":"Wei-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-7994","authenticated-orcid":false,"given":"Chih-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-4740","authenticated-orcid":false,"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast cancer heterogeneity and its implication in personalized precision therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2025.218225_bib3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Targeted Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.218225_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.canlet.2025.218225_bib7","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.canlet.2025.218225_bib9","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.218225_bib10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.canlet.2025.218225_bib11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canlet.2025.218225_bib12","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers15041320","article-title":"Targeted therapy and mechanisms of drug resistance in breast cancer","volume":"15","author":"Kinnel","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.canlet.2025.218225_bib13","first-page":"2920","article-title":"Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches","volume":"12","author":"Tufail","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218225_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"Bmj"},{"key":"10.1016\/j.canlet.2025.218225_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218225_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104351","article-title":"Recent strategies to overcome breast cancer resistance","volume":"197","author":"Khan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"S1","key":"10.1016\/j.canlet.2025.218225_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","article-title":"Triple\u2010negative breast cancer: an unmet medical need","volume":"16","author":"Hudis","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2025.218225_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrm1662","article-title":"Eph receptor signalling casts a wide net on cell behaviour","volume":"6","author":"Pasquale","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.canlet.2025.218225_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrm856","article-title":"Mechanisms and functions of Eph and ephrin signalling","volume":"3","author":"Kullander","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.canlet.2025.218225_bib21","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009159","article-title":"Eph receptor signaling and ephrins","volume":"5","author":"Lisabeth","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2025.218225_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cytogfr.2004.09.002","article-title":"The role of ephrins and Eph receptors in cancer","volume":"15","author":"Surawska","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.canlet.2025.218225_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.tibs.2024.10.002","article-title":"Eph receptor signaling complexes in the plasma membrane","volume":"49","author":"Pasquale","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2025.218225_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2014.06.010","article-title":"Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers","volume":"189","author":"Nagano","year":"2014","journal-title":"J. Contr. Release"},{"issue":"4","key":"10.1016\/j.canlet.2025.218225_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101817","article-title":"Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer","volume":"298","author":"Cha","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.canlet.2025.218225_bib27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/cam4.156","article-title":"Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients","volume":"2","author":"Nagano","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2025.218225_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109031","article-title":"EphA10 drives tumor progression and immune evasion by regulating the MAPK\/ERK cascade in lung adenocarcinoma","volume":"110","author":"Zhao","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"14","key":"10.1016\/j.canlet.2025.218225_bib29","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-18-0040","article-title":"Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2025.218225_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144712","article-title":"A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy","volume":"10","author":"Taki","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.canlet.2025.218225_bib31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pract."},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceutical medicine"},{"issue":"7971","key":"10.1016\/j.canlet.2025.218225_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218225_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216871","article-title":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors","volume":"591","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217083","article-title":"The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the Sphinx?","volume":"597","author":"Zhou","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"19","key":"10.1016\/j.canlet.2025.218225_bib37","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody\u2010drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun."},{"issue":"6","key":"10.1016\/j.canlet.2025.218225_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218225_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215969","article-title":"Drug conjugate-based anticancer therapy-current status and perspectives","volume":"552","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2025.218225_bib43","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.218225_bib44","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.62347\/FOWU3488","article-title":"Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2025.218225_bib45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218225_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple negative breast cancer (TNBC)\u2013Unleashing the power of antibody-drug conjugates (ADCs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2025.218225_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","article-title":"Triple-negative breast cancer therapeutic resistance: where is the Achilles' heel?","volume":"497","author":"Bai","year":"2021","journal-title":"Cancer letters"},{"issue":"8","key":"10.1016\/j.canlet.2025.218225_bib49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.218225_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.canlet.2025.218225_bib52","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases","volume":"30","author":"Medina","year":"2008","journal-title":"Clin. Ther."},{"issue":"14","key":"10.1016\/j.canlet.2025.218225_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173757","article-title":"FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1\/MRE11-mediated DNA repair in breast cancer models","volume":"135","author":"Chen","year":"2025","journal-title":"J Clin Invest."},{"issue":"35","key":"10.1016\/j.canlet.2025.218225_bib54","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5700","article-title":"Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1\/MAPK-dependent interleukin-6","volume":"6","author":"Hsiao","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.canlet.2025.218225_bib55","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1124\/mol.112.082743","article-title":"Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor\/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells","volume":"83","author":"Hsia","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218225_bib56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ijc.35271","article-title":"Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4\u2010overexpressing breast cancer cells","volume":"156","author":"Cheng","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2025.218225_bib57","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"Gy\u0151rffy","year":"2024","journal-title":"Innovation"},{"issue":"8016","key":"10.1016\/j.canlet.2025.218225_bib58","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2025.218225_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nprot.2016.169","article-title":"The ClusPro web server for protein\u2013protein docking","volume":"12","author":"Kozakov","year":"2017","journal-title":"Nat. Protoc."},{"issue":"W1","key":"10.1016\/j.canlet.2025.218225_bib60","doi-asserted-by":"crossref","first-page":"W333","DOI":"10.1093\/nar\/gkt450","article-title":"BeAtMuSiC: prediction of changes in protein\u2013protein binding affinity on mutations","volume":"41","author":"Dehouck","year":"2013","journal-title":"Nucleic acids research"},{"issue":"9","key":"10.1016\/j.canlet.2025.218225_bib61","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1093\/bioinformatics\/btaa026","article-title":"BAlaS: fast, interactive and accessible computational alanine-scanning using BudeAlaScan","volume":"36","author":"Wood","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.218225_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities","author":"Sabit","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.218225_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202070033","article-title":"BRCA1 deficiency impairs mitophagy and promotes inflammasome activation and mammary tumor metastasis","volume":"7","author":"Chen","year":"2020","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib65","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/s41467-020-16936-9","article-title":"NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation","volume":"11","author":"Miao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218225_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib67","article-title":"CDK4\/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib68","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.218225_bib69","first-page":"1209","article-title":"Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells","volume":"13","author":"Nie","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218225_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217453","article-title":"Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells","volume":"611","author":"Usama","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216024","article-title":"An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs","volume":"554","author":"Gandullo-S\u00e1nchez","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216355","article-title":"Highly proliferative and hypodifferentiated CAR-T cells targeting B7\u2013H3 enhance antitumor activity against ovarian and triple-negative breast cancers","volume":"572","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216413","article-title":"Epigenetic regulation of pyroptosis in cancer: molecular pathogenesis and targeting strategies","volume":"575","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib74","article-title":"Unlocking c-MET: a comprehensive journey into targeted therapies for breast cancer","volume":"588","author":"Kaboli","year":"2024","journal-title":"Cancer letters"},{"key":"10.1016\/j.canlet.2025.218225_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217219","article-title":"Combined inhibition of CDK4\/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer","volume":"604","author":"Chica-Parrado","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216036","article-title":"Extracellular vesicles as a novel approach for breast cancer therapeutics","volume":"555","author":"Lee","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218225_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216142","article-title":"Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF\u03b2 signaling pathway","volume":"560","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.canlet.2025.218225_bib78","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1042\/BCJ20210572","article-title":"The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs","volume":"478","author":"Liang","year":"2021","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218225_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915980","article-title":"Novel antibody\u2013drug conjugates for triple negative breast cancer","volume":"12","author":"Nagayama","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2025.218225_bib81","first-page":"14","article-title":"HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs","volume":"7","author":"Zeng","year":"2024","journal-title":"Cancer Drug Resistance"},{"issue":"5","key":"10.1016\/j.canlet.2025.218225_bib82","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cancers13051047","article-title":"HER2-\/HER3-targeting antibody\u2014drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors","volume":"13","author":"Yonesaka","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.canlet.2025.218225_bib83","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.3390\/molecules26102943","article-title":"Antibody\u2013drug conjugates\u2014a tutorial review","volume":"26","author":"Baah","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.canlet.2025.218225_bib84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"issue":"5\u20136","key":"10.1016\/j.canlet.2025.218225_bib85","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2006.01.026","article-title":"Engineering of therapeutic antibodies to minimize immunogenicity and optimize function","volume":"58","author":"Presta","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.canlet.2025.218225_bib86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"issue":"6069","key":"10.1016\/j.canlet.2025.218225_bib87","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2025.218225_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/02648725.2013.801235","article-title":"Antibody humanization methods\u2013a review and update","volume":"29","author":"Safdari","year":"2013","journal-title":"Biotechnol. Genet. Eng. Rev."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:38:31Z","timestamp":1792096711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":88,"alternative-id":["S0304383525007979"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218225","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218225"}}